Lexicon Pharmaceuticals, Inc.
LXRX
$2.32
-$0.02-0.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -97.60% | 1,572.11% | -79.31% | 710.40% | 1,652.64% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -97.60% | 1,572.11% | -79.31% | 710.40% | 1,652.64% |
| Cost of Revenue | 10.79% | -16.10% | 16.07% | -27.40% | -11.39% |
| Gross Profit | -228.31% | 158.55% | -37.55% | 80.98% | 180.97% |
| SG&A Expenses | 4.28% | -20.45% | -72.85% | -80.80% | -76.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.36% | -17.98% | -65.16% | -59.71% | -55.91% |
| Operating Income | -810.39% | 96.12% | 53.28% | 80.87% | 106.75% |
| Income Before Tax | -1,077.09% | 95.88% | 54.01% | 80.30% | 106.09% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1,077.09% | 95.88% | 54.01% | 80.30% | 106.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,077.09% | 95.88% | 54.01% | 80.30% | 106.09% |
| EBIT | -810.39% | 96.12% | 53.28% | 80.87% | 106.75% |
| EBITDA | -775.82% | 96.53% | 53.47% | 81.07% | 107.09% |
| EPS Basic | -906.67% | 96.28% | 54.28% | 80.42% | 105.24% |
| Normalized Basic EPS | -800.00% | 96.34% | 52.74% | 80.37% | 105.21% |
| EPS Diluted | -906.67% | 96.28% | 54.28% | 80.42% | 105.24% |
| Normalized Diluted EPS | -800.00% | 96.34% | 52.74% | 80.37% | 105.21% |
| Average Basic Shares Outstanding | 20.47% | 10.54% | 0.54% | 0.53% | 16.88% |
| Average Diluted Shares Outstanding | 20.38% | 10.54% | 0.54% | 0.53% | 16.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |